Endro Plus Flavour Tablets for Dogs

Main information

  • Trade name:
  • Endro Plus Flavour Tablets for Dogs
  • Pharmaceutical form:
  • Tablet
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Endro Plus Flavour Tablets for Dogs
    United Kingdom
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • febantel, combinations
  • Therapeutic area:
  • Dogs

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0340/001
  • Authorization date:
  • 01-06-2012
  • EU code:
  • UK/V/0340/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Issued:March2011

AN:02516/2008

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

EndroPlusFlavourTabletsfordogs

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

Eachtabletcontains:

Activesubstances:

Praziquantel 50mg

Pyrantelembonate 144mg

Febantel 150mg

Excipients:

Forafulllistofexcipients,seesection6.1.

3. PHARMACEUTICALFORM

Tablets.

Round,yellow,uncoatedtabletswithvisibledarkerspotsandbevellededgeswith

crosslineononesideandplainonotherside.

Thetabletscanbedividedintoequalhalvesorequalquarters.

4. CLINICALPARTICULARS

4.1 Targetspecies

Dogs(smallandmediumsize)

4.2 Indicationsforuse,specifyingthetargetspecies

Forthetreatmentofmixedinfestationswiththefollowingroundwormsand

tapewormsinadultdogsandpuppies:

Nematodes

Ascarids: Toxocaracanis,Toxascarisleonina(lateimmatureformsand

matureforms)

Hookworms:Uncinariastenocephala,Ancylostomacaninum(adults)

Cestodes

Tapeworms:Taeniaspp.,Dipylidiumcaninum

4.3 Contraindications

Donotusesimultaneouslywithpiperazinecompounds.

Donotexceedthestateddosagewhentreatingpregnantbitches.

Donotuseinanimalswithaknownhypersensitivitytotheactivesubstanceorto

anyofexcipients.

Notforuseindogsyoungerthan2weeksofageand/orweighinglessthan2kg.

Issued:March2011

AN:02516/2008

4.4 Specialwarningsforeachtargetspecies

Fleasserveasintermediatehostsforonecommontypeoftapeworm –Dipylidium

caninum.Tapeworminfestationiscertaintore-occurunlesscontrolofintermediate

hostsasfleas,miceetcisundertaken.

4.5 Specialprecautionsforuse

Specialprecautionsforuseinanimals

Anypart-usedtabletsshouldbediscarded.

Specialprecautionstobetakenbythepersonadministeringtheveterinary

medicinalproducttoanimals

Intheinterestsofgoodhygiene,personsadministeringthetabletdirectlytoadog

orbyaddingittothedog'sfood,shouldwashtheirhandsafterwards.

Incaseofaccidentalingestion,seekmedicaladviceandshowthepackageleaflet

tothephysician.

4.6Adversereactions(frequencyandseriousness)

Inrarecasestransientloosefaeces,diarrhoeaand/orvomitingmayoccurinsome

puppies.

4.7Useduringpregnancy,lactationorlay

Consultaveterinarysurgeonbeforetreatingpregnantanimalsforroundworms.

Thetabletsmaybeusedduringlactation(seeSection4.3and4.9).

Donotuseinbitchesduringthefirsttwo-thirdsofpregnancy.

4.8Interactionwithothermedicinalproductsandotherformsofinteraction

Donotcombinewithpiperazineastheanthelminticeffectsofpyranteland

piperazine(usedinmanywormingproductsfordogs)maybeantagonized.

Concurrentusewithothercholinergiccompoundscanleadtotoxicity.

Issued:March2011

AN:02516/2008

4.9 Amountstobeadministeredandadministrationroute

Fororaladministration.

Dosage

Therecommendeddoseratesare:15mg/kgbodyweightfebantel,14.4mg/kg

pyranteland5mg/kgpraziquantel.Thisisequivalentto1tabletper10kg

bodyweight.

Tabletsmaybehalved/quarteredtoallowaccuracyofdosing.

AdministrationandDurationofTreatment

Thetablet(s)canbegivendirectlytothedogordisguisedinfood.Norestrictionof

accesstofoodisrequiredeitherbeforeorafteradministrationoftheproduct.

Toensureadministrationofacorrectdose,bodyweightshouldbedeterminedas

accuratelyaspossible.

Puppiesmaybewormedwiththisproductfrom2weeksofageandevery2weeks

until12weeksofage.Thereaftertheyshouldbetreatedat3monthlyintervals.Itis

advisabletotreatthebitchatthesametimeasthepuppies.

ForthecontrolofToxocara,nursingbitchesshouldbedosed2weeksaftergiving

birthandevery2weeksuntilweaning.

Forroutinecontrolasingledoseisrecommendedat3monthlyintervals.

Intheeventofaheavyroundworminfestation,arepeatdoseshouldbegivenafter

14days.

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Benzimidazolespossesswidesafetymargin.Pyrantelisnotabsorbed

systematicallytoanyextent.Praziquantelalsohasawidesafetymargin,ofupto

fivetimestherecommendeddose.

4.11Withdrawalperiod

Notapplicable.

5. PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:Anthelmintics,ATCvetcode:QP52AC55

Issued:March2011

AN:02516/2008

5.1 Pharmacodynamicproperties

Theproductcontainsanthelminticsactiveagainstroundwormsandtapeworms.The

productcontainsthreeactivesubstances:febantel,pyrantelembonate(pamoate)

andpraziquantel,apartiallyhydrogenatedpyrazino-isoquinolinederivativeused

widelyasananthelminticforbothhumanandveterinaryuse. Pyrantelactsasa

cholinergicagonist.Itsmodeofactionistostimulatenicotiniccholinergicreceptors

oftheparasite,inducespasticparalysisandtherebyallowremovalfromthegastro-

intestinal(GI)systembyperistalsis.

Withthemammaliansystemfebantelundergoesringclosureformingfenbendazole

andoxfendazole.Itisthesechemicalentitieswhichexerttheanthelminticeffectby

inhibitionoftubulinpolymerization.Formationofmicrotubulesistherebyprevented,

resultingindisruptiontostructuresvitaltothenormalfunctioningofthehelminth.

Glucoseuptake,inparticular,isaffected,leadingtodepletionincellATP.The

parasitediesuponexhaustionofitsenergyreserves,whichoccurs2 –3dayslater.

Praziquantelisveryrapidlyabsorbedanddistributedthroughouttheparasite.Both

invitroandinvivostudieshaveshownthatpraziquantelcausesseveredamageto

theparasiteintegument,resultingincontractionandparalysis.Thereisanalmost

instantaneoustetaniccontractionoftheparasitemusculatureandarapid

vacuolisationofthesyncytialtegument.Thisrapidcontractionhasbeenexplained

bychangesindivalentcationfluxes,especiallycalcium.

Inthisfixedcombinationproductpyrantelandfebantelactsynergisticallyagainstall

relevantnematodes(ascaridsandhookworms)indogs.Inparticular,theactivity

spectrumcoversToxocaracanis,Toxascarisleonina,Uncinariastenocephalaand

Ancylostomacaninum.Thespectrumofactivityofpraziquntelcoversalsocestode

speciesindogs,inparticularallTaeniaspp.andDipylidiumcaninum.Praziquantel

actsagainstadultandimmatureformsoftheseparasites.

5.2Pharmacokineticparticulars

Perorallyadministeredpraziquantelisabsorbedalmostcompletelyfromthe

intestinaltract.Afterabsorption,thedrugisdistributedtoallorgans.Praziquantelis

metabolizedintoinactiveformsintheliverandsecretedinbile.Itisexcretedwithin

24hourstomorethan95%oftheadministereddosage.Onlytracesofnon-

metabolisedpraziquantelareexcreted.

Thepamoatesaltofpyrantelhaslowaqueoussolubility,anattributethatreduces

absorptionfromthegutandallowsthedrugtoreachandbeeffectiveagainst

parasitesinthelargeintestine.Becauseofthelowsystemicabsorptionofpyrantel

pamoate,thereisverylittledangerofadversereactions/toxicityinthehost.

Followingabsorption,pyrantelpamoateisquicklyandalmostcompletely

metabolizedintoinactivemetabolitesthatareexcretedrapidlyintheurine.

Febantelisabsorbedrelativelyrapidlyandmetabolizedtoanumberofmetabolites

includingfenbendazoleandoxfendazole,whichhaveanthelminticactivity.

Issued:March2011

AN:02516/2008

6. PHARMACEUTICALPARTICULARS

6.1Listofexcipients

LactoseMonohydrate

MaizeStarch

PovidoneK-30

SodiumLaurylSulfate

MicrocrystallineCellulose

ColloidalAnhydrousSilica

MagnesiumStearate

MeatFlavour

6.2Incompatibilities

Noneknown.

6.3Shelflife

Shelf-lifeoftheveterinarymedicinalproductaspackagedforsale:2years.

6.4Specialprecautionsforstorage

Thismedicinalproductdoesnotrequireanyspecialstorageconditions.

6.5Natureandcompositionofimmediatepackaging

Natureofcontainer:PrintandperforatedAlu-Alublister.Foldingboxasanouter

package.

Contentofcontainer:2tbl.,4tbl.,10tbl.,30tbl.,50tbl.,100tbland300tbl.

Notallpacksizesmaybemarketed.

6.6Specialprecautionsforthedisposalofunusedveterinarymedicinalproduct

orwastematerialsderivedfromtheuseofsuchproducts

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuch

veterinarymedicinalproductsshouldbedisposedofinaccordancewithlocal

requirements.

Issued:March2011

AN:02516/2008

7. MARKETINGAUTHORISATIONHOLDER

KRKAd.d,Novomesto

Šmarješkacesta6

8501Novomesto

Slovenia

8. MARKETINGAUTHORISATIONNUMBER

Vm01656/4015

9. DATEOFFIRSTAUTHORISATION

7March2011

10. DATEOFREVISIONOFTHETEXT

March2011

7-12-2018

Re‐evaluation of propane‐1,2‐diol esters of fatty acids (E 477) as a food additive

Re‐evaluation of propane‐1,2‐diol esters of fatty acids (E 477) as a food additive

Published on: Thu, 06 Dec 2018 The EFSA Panel on Food Additives and Flavourings (FAF) provides a scientific opinion re‐evaluating the safety of propane‐1,2‐diol esters of fatty acids (E 477) when used as a food additive. The Scientific Committee on Food (SCF) in 1978 endorsed the acceptable daily intake (ADI) of 25 mg/kg body weight (bw) per day, expressed as propane‐1,2‐diol, established by the Joint FAO/WHO Expert Committee on Food Additives (JECFA) in 1974. No adverse effects were observed in short‐t...

Europe - EFSA - European Food Safety Authority Publications

4-12-2018

FDA Approves Pexion for Treating Noise Aversion in Dogs

FDA Approves Pexion for Treating Noise Aversion in Dogs

The U.S. Food and Drug Administration announced today that its Center for Veterinary Medicine has approved Pexion (imepitoin tablets) to treat noise aversion in dogs. Dogs with noise aversion are sensitive to loud noises such as fireworks, street/traffic noises, and gun shots.

FDA - U.S. Food and Drug Administration

There are no news related to this product.